Biokin Pharmaceutical is based in Chengdu, China. It has raised $696M in total funding. Latest round: IPO.
Biokin Pharmaceutical funding overview
Biokin Pharmaceutical is based in Chengdu, China. Biokin Pharmaceutical has raised $696M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is an IPO announced in January 2023. The round record for Biokin Pharmaceutical runs through 2023; nothing later has been disclosed. Investors on record include GL Capital, Rongxi Venture Capital, Xinxi Investment, OrbiMed Advisors. 4 distinct backers are named across the disclosed rounds.
Frequently asked about Biokin Pharmaceutical funding
How much has Biokin Pharmaceutical raised?
Biokin Pharmaceutical has raised $696M in total disclosed funding across the rounds on record.
Who has invested in Biokin Pharmaceutical?
GL Capital, Rongxi Venture Capital, Xinxi Investment, OrbiMed Advisors are named among the investors backing Biokin Pharmaceutical.
What was the latest Biokin Pharmaceutical funding round?
The most recent disclosed round is an IPO, announced in January 2023.
Where is Biokin Pharmaceutical based?
Biokin Pharmaceutical is based in Chengdu, China.
When did Biokin Pharmaceutical last raise?
The last disclosed Biokin Pharmaceutical round closed in January 2023 at IPO.
We update the Biokin Pharmaceutical record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Chengdu and their backers are listed below.
